Welcome to our dedicated page for BIORA THERAPEUTICS news (Ticker: BIOR), a resource for investors and traders seeking the latest updates and insights on BIORA THERAPEUTICS stock.
Biora Therapeutics Inc. (BIOR) is a clinical-stage biotechnology company pioneering smart pill-based drug delivery systems for targeted and systemic therapies. This page provides investors and stakeholders with timely updates on the company’s progress in redefining treatment for gastrointestinal diseases and chronic conditions.
Access the latest press releases, clinical trial milestones, and financial reports related to Biora’s innovative platforms—including the NaviCap™ targeted colon release system and BioJet™ needle-free delivery technology. Stay informed about regulatory developments, research collaborations, and strategic partnerships shaping the future of oral biotherapeutics.
This resource is designed for efficient tracking of BIOR’s advancements in drug-device combinations and precision medicine. Bookmark this page or check back regularly for verified updates directly from the company and trusted financial news sources.
Rhea-AI Summary
Biora Therapeutics, Inc. (Nasdaq: BIOR) will report financial results and provide a corporate update for Q4 and full year 2023 on March 26, 2024. A webcast and conference call will be hosted by the company's management. Details for the call are provided for interested parties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
-
Rhea-AI Summary
Biora Therapeutics, Inc. secures $3 million in nondilutive capital through the monetization of legacy assets and $2.8 million in new capital from a convertible notes exchange with Context Capital. The company has significantly reduced its debt by over $80 million and attracted $19.8 million in new capital from institutional investors. Biora continues to optimize its capital structure and advance its therapeutic programs, with upcoming data release from the SAD portion of its phase 1 clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.72%
Tags
-
Rhea-AI Summary
Biora Therapeutics, Inc. completes SAD cohorts for BT-600 clinical study, with MAD dosing to start in March. The drug-device combination aims to treat ulcerative colitis by delivering tofacitinib directly to the colon for improved efficacy and reduced adverse events. Data from the SAD portion to be shared in March corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.67%
Tags
News
Rhea-AI Summary
Biora Therapeutics, Inc. (Nasdaq: BIOR) will participate in the Inflammatory Bowel Disease Symposium hosted virtually by Canaccord Genuity Capital Markets on February 28, 2024. Ariella Kelman, M.D., Chief Medical Officer, will participate in the panel titled 'The Next Evolutionary Steps in Addressing IBD.'
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.57%
Tags
-
Rhea-AI Summary
Biora Therapeutics, Inc. (Nasdaq: BIOR) will participate in a virtual fireside chat hosted by H.C. Wainwright & Co. to discuss the company’s delivery platforms addressing significant therapeutics indications, including its first ongoing clinical trial. The event is scheduled for January 29, 2024, at 11:00 AM Eastern / 8:00 AM Pacific. Adi Mohanty, CEO, Ariella Kelman, M.D., CMO, and Eric d’Esparbes, CFO, will be the speakers. A live webcast and replay of the fireside chat session will be available through the Investor Relations section of the Biora website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
-
Rhea-AI Summary
Biora Therapeutics, Inc. (Nasdaq: BIOR) provided guidance on anticipated milestones in 2024, including clinical study results for NaviCap™ Targeted Oral Delivery Platform and progress on pharma partnerships for BioJet™ Systemic Oral Delivery Platform. The company completed a transformation in 2023, laying the foundation for significant value inflection. The phase 1 study for BT-600, a de-risking step in NaviCap™ platform development, is underway. The company expects to progress relationships with large pharma companies for the BioJet platform, potentially providing non-dilutive funding for further development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
Rhea-AI Summary
Biora Therapeutics, a biotech company listed on Nasdaq as BIOR, announced the initiation of its phase 1, first-in-human clinical study of BT-600, a drug-device combination program designed to deliver a unique, liquid formulation of tofacitinib to the colon for the potential treatment of moderate to severe ulcerative colitis. The study aims to evaluate the safety, pharmacokinetics, and pharmacodynamics of BT-600 in healthy adult volunteers, with expectations of increased colonic tissue drug levels and reduced systemic levels compared with conventional oral tofacitinib.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.19%
Tags
-
News
Rhea-AI Summary
Biora Therapeutics, Inc. (Nasdaq: BIOR) announced that its BioJet™ Systemic Oral Delivery Platform has exceeded performance targets in a preclinical study conducted in collaboration with AstraZeneca. The study demonstrated greater than 25% bioavailability compared to subcutaneous delivery, showcasing the platform's potential to deliver multi-milligram liquid doses similar to injection with minimal to no formulation changes. The company continues to generate promising results, enabling further development under the collaboration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
-
Rhea-AI Summary
Biora Therapeutics, Inc. (Nasdaq: BIOR) announces receipt of US Patent No. 11,857,669 for targeted delivery of JAK inhibitors to the gastrointestinal tract, a significant win for its BT-600 program and NaviCap™ targeted oral delivery platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
News
Rhea-AI Summary
Biora Therapeutics, Inc. (Nasdaq: BIOR) announced an agreement with institutional investors to reduce the company’s net debt by 60% through a convertible note exchange, bringing $16.7 million in new capital. The company has reduced its debt by $83 million in 2023, achieving a 75% overall reduction. The transaction demonstrates investor confidence in the company's innovative technologies and near-term catalysts for its NaviCap™ and BioJet™ platforms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.5%
Tags
BIORA THERAPEUTICS INC